CN112168834A

CN112168834A - Application of picroside I in preparation of medicine for preventing and treating hepatic fibrosis

Info

Publication number: CN112168834A
Application number: CN202011084929.9A
Authority: CN
Inventors: 韩涵; 兰继平; 张彤; 熊凯; 石梦鸽; 金旻逸
Original assignee: Shanghai University of Traditional Chinese Medicine
Current assignee: Shanghai University of Traditional Chinese Medicine
Priority date: 2020-10-12
Filing date: 2020-10-12
Publication date: 2021-01-05

Abstract

The invention discloses application of picroside I in preparing a medicament for preventing and treating hepatic fibrosis, and researches show that the picroside I can obviously reduce various components in serum which react with hepatic fibrosis, reduce degeneration and necrosis of liver cells and infiltration of inflammatory cells, effectively reduce collagen fiber accumulation in liver tissues, show obvious liver protection effect, have good hepatic fibrosis resistance effect and have great application prospects.

Description

Application of picroside I in preparation of medicine for preventing and treating hepatic fibrosis

Technical Field

The invention belongs to the technical field of medicines and traditional Chinese medicines, relates to a new medical application of picroside I, and particularly relates to an application of picroside I in preparing a medicine for preventing and treating hepatic fibrosis.

Background

Picrorhiza scrophulariiflora Pennell (Picrorhiza scrophulariiflora Pennell) is a perennial herb of ScrophulariaceaePerennial herbs and hairs. Similar to Huang Lian in name, they are bitter and cold heat-clearing and dampness-drying herbs, good at removing gastrointestinal damp-heat, and also good at treating damp-heat dysentery. Modern pharmacological research shows that picrorhiza rhizome has the functions of protecting liver, benefiting gallbladder, resisting fungi, etc. The intensive research aiming at the liver protection and gallbladder function of picrorhiza rhizome mainly aims at picrorhiza rhizome total glycosides or picrorhiza rhizome II. Picroside I (Picroside I) is a natural iridoid component, exists in picrorhiza rhizome, is one of the main active substances, and has a chemical formula of C₂₄H₂₈O₁₁The molecular weight is 492.47, and the current research on Picroside I (Picroside I) is relatively lacked.

Hepatic fibrosis is a precursor process of liver cirrhosis and is a necessary pathological process for various chronic liver diseases to develop into liver cirrhosis. Liver cirrhosis is a disease that seriously threatens human health, and patients often die due to various complications and liver function failure. Current research generally considers cirrhosis to be an irreversible chronic progressive liver disease, but liver fibrosis is a reversible pathological change. Therefore, inhibiting the occurrence and development of liver fibrosis is the key to preventing chronic liver disease from developing into liver cirrhosis, and has important clinical significance for the research of liver fibrosis treatment. To date, a great deal of research on the mechanism of liver fibrosis has made people increasingly aware of liver fibrosis, but there is no clinically satisfactory drug for preventing the formation and progression of liver fibrosis.

Therefore, the development of a medicament which can successfully prevent the formation and the progress of hepatic fibrosis in clinic has a practical significance.

Disclosure of Invention

The invention aims to overcome the defect that no satisfactory medicine for preventing the formation and the development of hepatic fibrosis exists in the prior art clinically, and provides a medicine which can successfully prevent the formation and the development of hepatic fibrosis clinically, namely a new application field for expanding the traditional picroside I of Picrorhiza scrophulariiflora Pennell (Scrophulariaceae) extract. The picroside I is applied to the treatment of hepatic fibrosis, and has an obvious effect, namely the picroside I has a positive effect on resisting the hepatic fibrosis.

In order to achieve the purpose, the invention provides the following technical scheme:

application of picroside I in preparing medicine for preventing and treating hepatic fibrosis is provided.

Wherein picroside I is extracted from picrorhiza kurroa of picrorhiza of Scrophulariaceae, and is iridoid compound with molecular formula: c₂₄H₂₈O₁₁The structural formula is as follows:

the research of the invention finds that the picroside I can not only obviously reduce the levels of serum alkaline phosphatase, alanine Aminotransferase (ALT) and aspartate Aminotransferase (AST) of rats with liver injury, but also can obviously reduce the levels of acid phosphatase, phospholipid and lipid peroxide in the liver, thereby indicating that the picroside I has good anti-hepatic fibrosis effect, which is an important discovery in the liver protection and enzyme reduction of traditional Chinese medicines. In addition, the invention firstly discovers that the picroside I can reverse the increase of four indexes (type IV collagen, type III procollagen amino-terminal propeptide, laminin and hyaluronic acid) of mouse serum transaminase and liver fibers caused by hepatic fibrosis, and simultaneously can reduce the infiltration of inflammatory cells of liver cells and the accumulation of collagen fibers.

The specific action mechanism for treating hepatic fibrosis is as follows: the upstream CYP8B1 is up-regulated, the downstream cholic acid and taurocholic acid are down-regulated, and the metabolism of bile acid is regulated; glutathione levels are up-regulated, transglutaminase is down-regulated, and extracellular matrix accumulation is weakened; down-regulation of downstream sphingomyelin level, up-regulation of upstream sphingosine kinase 2, and weakening of pathological angiogenesis process; the metabolism of glycerophospholipids is improved, thereby reducing liver damage.

As a preferred technical scheme:

the application as described above, the form of the medicine for preventing and treating liver fibrosis comprises: oral tablets, granules, capsules and suspensions; the injection, powder injection, liposome, microemulsion and other common clinical preparations. The medicine for preventing and treating hepatic fibrosis can be matched with any pharmaceutically acceptable carrier (solid, semisolid or liquid) to prepare any pharmaceutically acceptable dosage form (tablets, injections, capsules and oral liquid). The scope of the present invention is not limited thereto, and only some of the possible technical solutions are listed here, which can be made into various dosage forms by conventional production methods known in the art, and the prevention, protection, treatment or scientific research of hepatic fibrosis and related diseases can be performed by oral administration or injection (including one or more of intravenous injection, intravenous drip, intraperitoneal injection, intramuscular injection, etc.).

The invention also provides a medicament for preventing and treating hepatic fibrosis, which contains picroside I, wherein the content of the picroside I in the medicament is within a certain range, namely the content of the picroside I is effective amount.

The use requirements are as follows: the administration mode is oral, and the dosage of the medicine is 12mg/kg/d picroside I corresponding to the body weight of a patient;

using the object: patients with hepatic fibrosis.

Has the advantages that:

the invention provides a new medical application of picroside I, in particular to an application of picroside I in preparing a medicine for preventing and treating hepatic fibrosis.

Drawings

FIG. 1 is an enlarged schematic view of a pathological section of mouse liver tissue (hematoxylin and eosin staining, 200X);

FIG. 2 is an enlarged schematic view of a pathological section of mouse liver tissue (sirius red stain, 200X);

FIG. 3 is a Western blot banding pattern;

wherein A, B, C and D in FIGS. 1 and 2 correspond to the blank control group, the model group, the positive drug group and the experimental group, respectively.

Detailed Description

The following further describes the embodiments of the present invention with reference to the attached drawings.

Example 1

The effect of picroside I on treating hepatic fibrosis of mice is as follows:

reagents and materials

C57BL/6 male mice, cleaning grade, body weight (20-22 g); picroside I, manufactured by Nanjing Guangrun Biotech Co., Ltd.

Second, Experimental methods

The animal experiment is divided into 4 groups, each group is divided into 12 animals according to body weight, and the animals are divided into blank group, model group, positive drug group and experimental group. Thioacetamide (dissolved in physiological saline, the same below) is used as a hepatic fibrosis induction drug, and the administration dosage is 200 mg/kg; s-adenosylmethionine is a positive drug, and the dosage is 10 mg/kg; picroside I in the experimental group is a candidate drug for resisting hepatic fibrosis, and the dosage is 75 mg/kg. Injecting normal saline into the abdominal cavity of the white control group mice every other day, and injecting thioacetamide into the abdominal cavity of the model group mice, the positive drug group mice and the experimental group mice for 8 weeks. Meanwhile, from the first week, the mice of the blank control group and the model group were gazed with physiological saline every day, the mice of the positive drug group were gazed with S-adenosylmethionine, and the mice of the experimental group were gazed with picroside I until the 8 th week. After the administration and the modeling are finished, the eyeballs are picked up to take blood, the blood is collected by a procoagulant tube, serum is centrifugally separated, and liver tissues are taken for standby examination.

Third, detecting the index

1. Serum detects the content of liver injury indexes ALT, SAT, type IV collagen (Collagen type IV, Col IV), type III procollagen amino-terminal propeptide (N-terminal peptide of type III procollagen, PC III NP), Laminin (LN) and Hyaluronic Acid (HA).

2. Liver h.e staining test and liver sirius red staining test (observing the area ratio of liver sirius red staining and red collagen fiber to detect the liver necrosis condition).

3. Proteomics research: qualitative analysis and comparison of liver protein, and screening the expression difference and bioinformatics analysis of each histone by using a statistical method. In addition, fluorescent quantitative PCR and western blot detection in liver: transforming growth factor beta (TGF-. beta.), tissue transglutaminase 2(Tgm2), Vimentin (Vimentin), annexin A2(Anxa2), retinol binding protein 1(Rbp1), galectin 3(galectin-3), CYP8B1, sphingosine kinase 2(Sphk2), and GAPDH.

Fourth, experimental results

1. The results of the content detection of the liver injury indexes ALT, SAT, type IV collagen (collagen type IV, Col IV), type III procollagen amino-terminal propeptide (N-terminal peptide of type III procollagen, PC III NP), Laminin (LN) and Hyaluronic Acid (HA):

a) the ALT content: compared with a control group, the experimental group has the advantages that the IU/L is remarkably reduced, namely a blank group (30.67 +/-3.98), a model group (107.33 +/-11.09), a positive medicine group (102.33 +/-7.51) and an experimental group (63.60 +/-13.81). P <0.05 compared to model group and positive drug group.

b) SAT content: compared with a control group, the experimental group has the advantages that IU/L of a blank group (125.83 +/-19.24), IU/L of a model group (202.17 +/-13.32), IU/L of a positive medicine group (176.67 +/-3.79) and IU/L of an experimental group (150.20 +/-14.99) are obviously reduced. P <0.05 compared to model group.

c) Content of Col IV: compared with a control group, the experimental group has the advantages that ng/L of a blank group (8.40 +/-0.64), ng/L of a model group (15.02 +/-0.97), ng/L of a positive medicine group (10.16 +/-0.46) and ng/L of an experimental group (11.43 +/-0.29) are obviously reduced. P <0.05 compared to model group.

d) The PC iii NP experimental group was significantly reduced relative to the control group: blank group (4.83 +/-0.39) ng/L, model group (9.05 +/-0.37) ng/L, positive drug group (5.85 +/-0.60) ng/L and experimental group (5.79 +/-0.58) ng/L. P <0.05 compared to model group.

e) LN content: compared with a control group, the experimental group has the advantages that ng/L of a blank group (150.59 +/-9.46), ng/L of a model group (256.15 +/-12.30), ng/L of a positive medicine group (185.14 +/-9.69) and ng/L of an experimental group (177.88 +/-8.12) are obviously reduced. P <0.05 compared to model group.

f) HA content: compared with a control group, the experimental group has the advantages that the ng/L of the blank group (22.92 +/-2.07), the ng/L of the model group (46.15 +/-1.32), the ng/L of the positive medicine group (33.73 +/-3.08) and the ng/L of the experimental group (35.10 +/-2.89) are obviously reduced. P <0.05 compared to model group.

In conclusion, 75mg/kg of picroside I can remarkably reduce the damage of the liver.

2. And (3) pathological detection results:

a) liver h.e staining assay: the results are shown in FIG. 1. The experimental group of the necrosis condition of the liver cells and the infiltration of the inflammatory cells is obviously reduced, which shows that the picroside I has obvious effect on treating the liver necrosis of the liver fibrosis. The blank control group mice had well-arranged hepatocytes, clear liver cord structures, and no necrosis or inflammatory reaction. The liver tissues of the mice in the model group can show wide and mild edema of liver cells, cell swelling, more liver cell swelling necrosis around central veins, occasional eosinophilic corpuscles, abnormal liver cell nuclei and different sizes, and more nuclear inclusion bodies can be seen to have inflammatory cell infiltration. The positive drug group can show liver cell swelling, abnormal nucleus and different sizes, and is mostly seen in nuclear inclusion bodies without obvious inflammatory reaction. In the experimental group, a small amount of liver cells around the central vein of the liver tissue of the mouse are not uniformly stained in cytoplasm, a small amount of nuclei are larger, and no obvious inflammatory reaction is seen. Therefore, the S-adenosylmethionine and the picroside I can effectively reduce thioacetamide-induced hepatocyte degeneration and inflammatory cell infiltration.

b) Liver sirius red staining test condition: the results are shown in FIG. 2. Little collagen fiber can be seen in the liver tissue of the blank control group mouse at the central vein, and criss-cross collagen fiber can be seen in the liver tissue of the model group mouse. After protection with S-adenosylmethionine or picroside I, the collagen fibril area was reduced and the high dose group had substantially no criss-cross red collagen fibrils. The area ratio analysis of the red collagen fibers by using Image J software shows that the area of the red area of the blank control group is only 1.42 percent, the area ratio of the model group is obviously increased (P is less than 0.01) and reaches 6.86 percent. The area ratio of the red collagen fiber is obviously reduced by the S-adenosylmethionine and the picroside I (P is less than 0.01). It can be seen that picroside I is effective in reducing collagen fiber accumulation in liver tissue caused by thioacetamide.

In conclusion, the picroside I can reduce the degeneration and necrosis of liver cells and the infiltration of inflammatory cells, effectively reduce the accumulation of collagen fibers in liver tissues, show a certain liver protection effect and have a certain hepatic fibrosis resistance effect.

3. Western blot detection and PCR results

Table 1 effect of picroside I on related proteins (n-5,

p <0.05, compared to a blank control group;^#p <0.05, comparison with model group)

	Blank group	Model set	Positive drug group	Experimental group
					Anxa2	0.75±0.16	1.37±0.17*	1.09±0.21	1.01±0.11#
TGF-β1	0.15±0.03	0.35±0.09*	0.19±0.06#	0.16±0.05#
					CYP8B1	1.82±0.31	0.65±0.10*	1.1±0.13#	0.95±0.11#
Tgm2	1.17±0.52	1.47±0.42*	1.52±0.69	0.95±0.25#
					Vimentin	0.36±0.07	1.51±0.06*	0.95±0.11#	0.62±0.08#
Rbp1	0.41±0.14	1.36±0.17*	0.78±0.07#	0.64±0.15#
					galectin-3	0.32±0.06	1.32±0.05*	0.71±0.09	0.40±0.13#
Sphk2	1.36±0.11	0.59±0.15*	1.10±0.08#	1.23±0.07#

Table 2 effect of picroside i on mRNA of the relevant difference protein (n-5,

p <0.05, compared to blank group;^#p <0.05, comparison with model group)

	Blank group	Model set	Positive drug group	Experimental group
					Anxa2	1.89±0.15	13.28±1.52	3.54±0.81	5.09±1.18
TGF-β1	1.77±0.13	3.58±0.99	2.29±0.66	2.16±0.85
					CYP8B1	2.12±0.61	0.75±0.11	1.15±0.53	1.95±0.41
Tgm2	13.74±1.72	11.17±0.92	10.52±1.09	6.97±1.25
					Vimentin	1.46±0.17	6.11±0.76	4.05±0.91	3.12±0.68
Rbp1	14.42±0.64	14.26±1.27	12.98±1.57	6.24±1.65
					Lgals-3	14.12±1.56	12.21±1.15	6.24±1.49	4.27±0.83
Sphk2	1.69±0.71	0.59±0.05	0.87±0.06	0.94±0.07

As shown in FIG. 3, tables 1 and 2, the levels of TGF-. beta.1, ValproTgm 2, Vim, Anxa2, retinol binding protein 1 and galectin-3 protein and their mRNA were significantly increased in the liver of the model group mice, while the levels of CYP8B1 and Sphk2 protein and their mRNA were significantly decreased (P < 0.05) compared to the blank group. Picroside I can obviously reduce the levels of TGF-beta 1, Tgm2, Vim, Anxa2, Rbp1, galectin-3 protein and mRNA thereof in mouse liver, and obviously increase the levels of CYP8B1, Sphk2 protein and mRNA thereof (P is less than 0.05).

And (4) experimental conclusion: the research of molecular biology shows that the picroside I can regulate the protein levels of transglutaminase 2, vimentin, CYP8B1, sphingosine kinase 2, annexin A2, retinol binding protein 1, galectin 3 and the like in liver tissues of liver fibrosis mice. Previous studies have also demonstrated the relevance of the above proteins to liver fibrosis.

In conclusion, the picroside I can reduce the degeneration and necrosis of liver cells and the infiltration of inflammatory cells, effectively reduce the accumulation of collagen fibers in liver tissues, show liver protection effect and have good anti-hepatic fibrosis effect. The action mechanism is that upstream CYP8B1 is up-regulated, downstream cholic acid and taurocholic acid are down-regulated, and the metabolism of bile acid is regulated; glutathione levels are up-regulated, transglutaminase is down-regulated, and extracellular matrix accumulation is weakened; down-regulation of downstream sphingomyelin level, up-regulation of upstream sphingosine kinase 2, and weakening of pathological angiogenesis process; the metabolism of glycerophospholipids is improved, thereby reducing liver damage.

Example 2

A preparation of picroside I is prepared by the following steps:

(1) preparation of picroside I granules:

taking a proper amount of picroside I, adding a proper amount of beta-cyclodextrin, sucrose and soluble starch (the mass ratio of the picroside I to the dextrin to the sucrose to the soluble starch is 1:2:3:4), preparing a soft material by using ethanol, preparing granules by using a 16-mesh sieve, and drying at the temperature of below 60 ℃ to obtain the picroside I granules which can be used for treating hepatic fibrosis.

(2) Preparation of picroside I tablets:

weighing and uniformly mixing the formula amount of picroside I, starch, dextrin and tartaric acid. 50% ethanol is added dropwise by a rubber head dropper, and stirring is carried out while adding until obvious particles appear. Granulating with 16 mesh sieve, drying at 60 deg.C for 15 min, and grading with 16 mesh sieve. And uniformly mixing the magnesium stearate with the whole granules according to the prescription amount, and tabletting by using a single-punch tablet machine to ensure that each tablet is 0.2-0.5 g in weight.

(3) Preparing a picroside I capsule:

weighing the formula amount of picroside I, crushing into fine powder, sieving, and filling into a No. 1 hollow capsule to obtain the picroside I capsule, wherein the filling amount is 0.4 g.

(4) Preparing picroside I oral liquid:

taking picroside I, crushing into fine powder, weighing 10 g, adding 500 times of water, mixing uniformly, adding 0.2% mannitol of a flavoring agent, 0.3% stevioside and 0.1% potassium sorbate of a preservative, adding distilled water to a constant volume of 10000ml, mixing uniformly, sterilizing, and subpackaging with 20 ml/bottle.

Although specific embodiments of the present invention have been described above, it will be appreciated by those skilled in the art that these embodiments are merely illustrative and various changes or modifications may be made without departing from the principles and spirit of the invention.

Claims

1. Application of picroside I in preparing medicine for preventing and treating hepatic fibrosis is provided.

2. The use according to claim 1, wherein the medicament for preventing and treating liver fibrosis is in the form of: oral tablets, granules, capsules and suspensions; injection, powder for injection, liposome and microemulsion.

3. A medicine for preventing and treating hepatic fibrosis is characterized in that the medicine contains picroside I.